ОЗОН Фармацевтика logo
ОЗОН Фармацевтика OZPH
report update icon

Quarterly report 2026-Q2
added 09-06-2026

ОЗОН Фармацевтика Financial Statements 2025-2021 | OZPH

Key Metrics ОЗОН Фармацевтика

2025 2024 2023 2022 2021

Operating Cash Flow Per Share

2.78 5.3 4.66 -0.994 2.77

Free Cash Flow Per Share

-0.26 1 4 -2 1

Cash Per Share

2.43 5.09 0.95 1.11 1.37

Price To Sales Ratio

2 2 2 2 2

Dividend Yield

0.021 0.011 - - -

Payout Ratio

0.2 0.1 - - -

Revenue Per Share

27.1 23.3 19.7 19 17.7

Net Income Per Share

5 4 4 4 4

Book Value Per Share

20 17 16 14 13

Tangible Book Value Per Share

20 17 16 14 13

Shareholders Equity Per Share

20 17 16 14 13

Interest Debt Per Share

10.1 14.1 9.26 11.4 7.91

Market Cap

60.1 B 45.6 B 35 B 35 B 35 B

Enterprise Value

69.1 B 55.5 B 43.3 B 45.3 B 41.5 B

P/E Ratio

10 10 9 10 9

P/OCF Ratio

18.5 7.82 7.51 -35.2 12.6

P/FCF Ratio

-82.3 29.4 8.85 -20.9 22.2

P/B Ratio

3 2 2 2 3

EV/Sales

2.19 2.17 2.2 2.38 2.34

EV/EBITDA

6 6 6 7 7

EV/OCF

21.3 9.52 9.29 -45.6 15

Earnings Yield

0.103 0.101 0.114 0.104 0.113

Free Cash Flow Yield

-0.005 0.027 0.109 -0.049 0.036

Debt To Equity

0.498 0.838 0.59 0.792 0.623

Debt To Assets

0.222 0.313 0.269 0.334 0.266

Net Debt To EBITDA

0.74 1 1 2 1

Interest Coverage

2.77 3.2 5.35 5.5 9.54

Income Quality

0.527 1.26 1.17 -0.272 0.701

Sales General And Administrative To Revenue

0.165 0.165 0.14 0.127 0.118

Capex To Operating Cash Flow

1.22 0.734 0.152 -0.686 0.43

Capex To Revenue

0.13 0.17 0.04 0.04 0.07

Capex To Depreciation

3.32 3.89 0.784 0.974 1.98

Return On Tangible Assets, ROTA

0.116 0.093 0.116 0.107 0.133

Tangible Asset Value

23.7 B 18.5 B 15.7 B 14.4 B 12.7 B

Invested Capital

35.5 B 34 B 25 B 25.8 B 20.6 B

Return On Equity, ROE

0.186 0.182 0.251 0.249 0.308

Capex Per Share

3.41 3.89 0.706 0.682 1.19

All numbers in RUB currency

Quarterly Key Metrics ОЗОН Фармацевтика

2026-Q2 2026-Q1 2025-Q4 2025-Q3 2025-Q2 2025-Q1

Price To Sales Ratio

1.52 1.79 1.9 2.05 1.87 2.06

Market Cap

50.3 B 56.7 B 60.1 B 59.2 B 49.2 B 57.2 B

Enterprise Value

55.3 B 64 B 69.1 B 69.8 B 58.9 B 67.9 B

P/E Ratio

6.53 8.76 9.74 12.8 14.2 11.8

P/B Ratio

2 1.63 2.53 1.93 2.38 2.17

EV/EBITDA

4.22 5.33 5.67 6.11 5.94 6.51

Return On Equity, ROE

0.214 0.187 0.186 0.151 0.119 0.183

All numbers in RUB currency

Financial statements are the primary tool companies use to inform stakeholders about their financial position, performance, and changes in capital structure. It is a kind of "business language" understood by investors, creditors, tax authorities, and other participants in the economic environment.

Main types of financial statements ОЗОН Фармацевтика OZPH
  1. Income Statement
    Shows income, expenses, and resulting profit or loss over a specific period. Helps assess business profitability.
  2. Balance Sheet
    Reflects a company’s assets, liabilities, and equity as of a specific date. It’s a snapshot of what the company owns and owes.
    Assets — everything the company owns (cash, equipment, buildings, accounts receivable, etc.).
    Liabilities — debts and other external sources of financing.
    Equity — owners' capital and retained earnings.
  3. Cash Flow Statement
    Reveals how the company earns and spends money in three areas: operating, investing, and financing activities.
International reporting standards
  • IFRS — International Financial Reporting Standards, applicable to public and multinational companies.
  • GAAP — Generally Accepted Accounting Principles used in the United States.
  • RAS — Russian Accounting Standards, used domestically in Russia.

Financial reporting ОЗОН Фармацевтика plays a crucial role for investors as it serves as an objective source of information about a company's current state. Based on the reports, one can determine whether a company is growing, stagnating, or losing market share. This allows investors to identify both promising and problematic assets in a timely manner.

In addition, financial data provides a basis for forecasting future returns. Historical trends in revenue, profit, and cash flow help evaluate potential dividends, the likelihood of stock price growth, and overall investment risk.

Transparent and accurate reporting is also an indicator of a company’s maturity and managerial responsibility. Such openness builds investor confidence and simplifies investment decision-making, especially when comparing multiple companies.

Finally, financial statements enable high-quality comparative analysis. They allow companies to be evaluated against each other in terms of profitability, debt levels, margins, and other key metrics — which is particularly important when choosing the best investment options within an industry or market segment.

Financial statements of other stocks in the Biotechnology industry

Issuer Price % 24h Market Cap Country
Фармсинтез Фармсинтез
LIFE
- - - russiaRussia
AbbVie AbbVie
ABBV
$ 257.12 0.86 % $ 455 B usaUSA
AbCellera Biologics AbCellera Biologics
ABCL
$ 10.89 4.11 % $ 3.25 B canadaCanada
Ayala Pharmaceuticals Ayala Pharmaceuticals
AYLA
- - $ 7.46 M israelIsrael
Amryt Pharma plc Amryt Pharma plc
AMYT
- - $ 621 M britainBritain
Evelo Biosciences Evelo Biosciences
EVLO
- -14.46 % $ 27.9 M usaUSA
ASLAN Pharmaceuticals Limited ASLAN Pharmaceuticals Limited
ASLN
- -14.27 % $ 1.7 M singaporeSingapore
Acorda Therapeutics Acorda Therapeutics
ACOR
- -24.86 % $ 820 K usaUSA
Adaptimmune Therapeutics plc Adaptimmune Therapeutics plc
ADAP
- -15.15 % $ 60.3 M britainBritain
Advaxis Advaxis
ADXS
- -9.65 % $ 45.9 M usaUSA
Abeona Therapeutics Abeona Therapeutics
ABEO
$ 5.42 0.18 % $ 287 M usaUSA
iTeos Therapeutics iTeos Therapeutics
ITOS
- - $ 411 M usaUSA
Galmed Pharmaceuticals Ltd. Galmed Pharmaceuticals Ltd.
GLMD
$ 4.63 21.05 % $ 20 M israelIsrael
Akouos Akouos
AKUS
- 0.23 % $ 488 M usaUSA
Albireo Pharma Albireo Pharma
ALBO
- -0.23 % $ 916 M usaUSA
BioXcel Therapeutics BioXcel Therapeutics
BTAI
$ 0.07 9.81 % $ 855 K usaUSA
Allakos Allakos
ALLK
- - $ 28.6 M usaUSA
Cyclerion Therapeutics Cyclerion Therapeutics
CYCN
$ 23.52 458.67 % $ 98.9 M usaUSA
Lexicon Pharmaceuticals Lexicon Pharmaceuticals
LXRX
$ 2.0 0.3 % $ 726 M usaUSA
Allena Pharmaceuticals Allena Pharmaceuticals
ALNA
- 3.16 % $ 1.9 M usaUSA
Alpine Immune Sciences Alpine Immune Sciences
ALPN
- - $ 2.17 B usaUSA
Arbutus Biopharma Corporation Arbutus Biopharma Corporation
ABUS
$ 5.12 0.1 % $ 981 M canadaCanada
Ampio Pharmaceuticals Ampio Pharmaceuticals
AMPE
- -11.43 % $ 502 K usaUSA
NextCure NextCure
NXTC
$ 7.0 0.55 % $ 19.9 M usaUSA
Aridis Pharmaceuticals Aridis Pharmaceuticals
ARDS
- 17.91 % $ 11.1 M usaUSA
Nanobiotix S.A. Nanobiotix S.A.
NBTX
$ 37.01 0.27 % $ 1.77 T franceFrance
ACADIA Pharmaceuticals ACADIA Pharmaceuticals
ACAD
$ 27.83 0.32 % $ 4.69 B usaUSA
Axcella Health Axcella Health
AXLA
- -16.42 % $ 249 M usaUSA
SQZ Biotechnologies Company SQZ Biotechnologies Company
SQZ
- 57.95 % $ 12.8 M usaUSA
Atreca Atreca
BCEL
- -11.76 % $ 5.79 M usaUSA
Berkeley Lights Berkeley Lights
BLI
- -7.31 % $ 87 M usaUSA
Bellerophon Therapeutics Bellerophon Therapeutics
BLPH
- -74.18 % $ 955 K usaUSA
Achieve Life Sciences Achieve Life Sciences
ACHV
$ 7.06 0.41 % $ 308 M usaUSA
Baudax Bio Baudax Bio
BXRX
- 0.59 % $ 63 K usaUSA
Calithera Biosciences Calithera Biosciences
CALA
- -10.95 % $ 876 K usaUSA
CymaBay Therapeutics CymaBay Therapeutics
CBAY
- - $ 3.45 B usaUSA
Codiak BioSciences Codiak BioSciences
CDAK
- -55.98 % $ 2.15 M usaUSA
ChemoCentryx ChemoCentryx
CCXI
- - $ 3.74 B usaUSA
Avid Bioservices Avid Bioservices
CDMO
- - $ 789 M usaUSA
AC Immune SA AC Immune SA
ACIU
$ 2.76 2.6 % $ 278 M schweizSchweiz
Cerevel Therapeutics Holdings Cerevel Therapeutics Holdings
CERE
- - $ 7.29 B usaUSA
Aclaris Therapeutics Aclaris Therapeutics
ACRS
$ 5.32 1.27 % $ 652 M usaUSA
Checkpoint Therapeutics Checkpoint Therapeutics
CKPT
- - $ 169 M usaUSA
Adagene Adagene
ADAG
$ 3.4 2.72 % $ 201 M chinaChina
ADC Therapeutics SA ADC Therapeutics SA
ADCT
$ 1.07 0.45 % $ 136 M schweizSchweiz
Adial Pharmaceuticals Adial Pharmaceuticals
ADIL
$ 4.9 0.08 % $ 3.28 M usaUSA
ADMA Biologics ADMA Biologics
ADMA
$ 9.23 0.16 % $ 2.2 B usaUSA
Adaptive Biotechnologies Corporation Adaptive Biotechnologies Corporation
ADPT
$ 24.2 0.08 % $ 3.67 B usaUSA
Agenus Agenus
AGEN
$ 6.94 0.73 % $ 206 M usaUSA
Agios Pharmaceuticals Agios Pharmaceuticals
AGIO
$ 33.6 0.16 % $ 1.95 B usaUSA